| 许明芳,黄 环,杨 怡.178例女性晚期非小细胞肺癌预后分析[J].中国肿瘤,2015,24(6):529-534. |
| 178例女性晚期非小细胞肺癌预后分析 |
| The Prognosis of Advanced Non-small Cell Lung Cancer in Female：A Clinical Analysis of 178 Cases |
| 投稿时间：2015-03-23 |
| DOI：10.11735/j.issn.1004-0242.2015.06.A019 |
|
 |
| 中文关键词: 非小细胞肺癌 女性 临床特征 治疗 预后 |
| 英文关键词:non-small cell lung cancer female clinical characteristics therapy prognostic |
| 基金项目: |
|
| 摘要点击次数: 1667 |
| 全文下载次数: 865 |
| 中文摘要: |
| 摘 要：［目的］ 总结女性晚期非小细胞肺癌患者的临床特征及治疗效果，分析影响预后的因素，为女性晚期非小细胞肺癌的个体化分层治疗提供依据。［方法］ 回顾性分析女性晚期非小细胞肺癌178例，收集资料包括年龄、病理类型、EGFR突变情况、肿瘤分期、一线治疗效果、无进展生存期（PFS）和总生存期（OS）。［结果］ 患者平均年龄58.0±11.3岁；腺癌占87.1%；接受EGFR基因检测患者中突变型占60.8%(31/51)；Ⅳ期患者占75.9%。接受针对肿瘤的治疗的169例患者中，一线治疗后客观有效率为52.3%，疾病控制率为84.9%。中位PFS为9.0个月，中位OS为22.0个月。Cox回归多因素分析显示：年龄、治疗线数和一线治疗效果均为OS独立预后因素(P＜0.05）。一线治疗进展后继续接受抗肿瘤治疗的患者的OS较终止治疗的患者显著延长(P＜0.05）。［结论］ 女性晚期非小细胞肺癌以腺癌为主，EGFR突变率较高，一线治疗效果、接受治疗线数对于女性晚期非小细胞肺癌有独立预后意义，一线治疗进展后继续接受抗肿瘤治疗的患者预后更好。 |
| 英文摘要: |
| Abstract：［Purpose］ To describe the clinical features and therapeutic respond，analyze the prognostic factors，and provide reference for individual treatment of advanced non-small cell lung cancer (NSCLC) in female. ［Methods］ The clinical data of 178 female patients with stage Ⅲ and Ⅳ NSCLC was collected. We collected information including age，histology，EGFR mutations，stage，therapy line，first-line therapeutic respond，progression-free survival(PFS) and overall survival (OS). ［Results］The average age was 58.0±11.3 years old. Adenocarcinoma was accounted for 87.1%. EGFR mutation was accounted for 60.8%(31/51).TNM Ⅳ was accounted for 75.9%. There were 169 patients receiving antineoplastic therapy and evaluation. The objective and efficient rate (ORR) was 52.3%. The disease control rate (DCR) was 84.9%.The median progression-free survival (PFS) was 9 months. The median OS was 22 months. Multivariate Cox analysis for OS showed that age，therapy line，first-line therapeutic respond and methods of the first-line therapy were independent prognostic factors (P＜0.05). The overall survival of patients who continued to receive antineoplastic therapy when tumor got progression after first-line therapy was significantly longer than those who stopped therapy(P＜0.05).［Conclusion］ Adenocarcinoma is the main histological type of advanced NSCLC in female，accompany with high rate of EGFR mutation. The age，therapy line，first-line therapeutic respond and methods of the first-line therapy are independent prognostic factors of advanced NSCLC in female. The patients who continued to receive antineoplastic therapy when tumor got progression after first-line therapy got a better prognosis. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |